CD11b, the α-chain of β 2 integrin Mac-1, is involved in many activation processes of phagocytes. Depending on the respective autoimmune disorder, CD11b has been shown to exert pro-inflammatory functions or be dispensable in their pathogenesis. Here, we investigated the role of CD11b in the pathogenesis of experimental epidermolysis bullosa acquisita (EBA), an autoimmune skin blistering disease mediated by autoantibodies to type VII collagen. Unexpectedly, in an antibody transfer-induced model of EBA, CD11b-deficient mice developed more severe disease symptoms than wild-type mice in the late phase of the disease. Furthermore, as compared to wild-type controls, CD11b-deficient mice expressed increased levels of circulating IFN-γ and IL-4. Taken together, for the first time, our results suggest an anti-inflammatory role for CD11b in experimental autoimmune diseases.
| BACKGROUND
Mac-1, a main β2 integrin, is a heterodimeric cell protein consisting of the common β2 subunit (CD18) and the specific α chain CD11b.
Being expressed in multiple cells, Mac-1 is involved in many biological and immunological processes, including cell trafficking, cell adhesion, phagocytosis and regulation of inflammatory responses. [1, 2] Due to its array of functions, the role of CD11b in immune-related diseases, for example autoimmune disorders, is heterogeneous and diverse. By investigating corresponding knockout mice, the role of CD11b in various experimental models of autoimmune diseases has been studied, and diverging results have been reported. For example, a pro-inflammatory role of CD11b has been suggested in experimental autoimmune encephalomyelitis (EAE) [3] and experimental bullous pemphigoid. [4] By contrast, a dispensable role of CD11b has been demonstrated in antibody transfer-induced arthritis [5] and in systemic lupus erythematosus (SLE)-like disease.
[6]
| QUESTIONS ADDRESSED
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease mediated by autoantibodies to type VII collagen (COL7). [7] Several mouse models have been established either by immunising mice with recombinant murine COL7 [8] or passively by transferring autoantibodies against murine COL7 into mice. [9, 10] In this study, we aimed at investigating the role of CD11b in experimental EBA. Due to the MHC restriction in the development of immunisation-induced EBA, we investigated whether CD11b plays a role in antibody transferinduced experimental EBA.
| EXPERIMENTAL DESIGN
Experimental EBA induced by antibody transfer can be conducted in two ways, as a systemic or a local model. The systemic model is induced by repetitive subcutaneous injection of antibodies into the skin and mice develop skin lesions from day 4 on after the first injection with an increase in disease severity over time. [10] The local model is induced by a single intradermal injection of antibodies into the ears. Here, mice start to exert disease symptoms already 24 hours after injection. [9] The different kinetics of disease development in the two models suggest differences in their underlying pathomechanisms. Therefore, we investigated the role of CD11b deficiency in both, systemic and local antibody transfer-induced EBA. To assess disease activity in experimental animals, mice were scored for clinical symptoms, and skin biopsies were evaluated histologically. Finally, levels of IFN-γ, IL-17A, IL-4 and IL-10, as well as antibodies against rabbit-mCOL7 IgG were determined in mouse sera to address the mechanism(s) behind the role of CD11b in experimental EBA.
| RESULTS
In the systemic model, both CD11b−/− and wild-type mice started to develop first symptoms 8 days after the first antibody injection and disease severity increased overtime. Until day 8 no significant difference in disease severity was observed between CD11b−/− mice and wild-type controls. However, unexpectedly, from day 12 on, symptoms in CD11b−/− mice were significantly stronger expressed than in wild-type controls ( Figure 1A ,B,C). This difference was also shown in histopathology of skin samples collected at day 16 from CD11b−/− mice and the corresponding controls ( Figure 1D ,E). However, deposition of rabbit anti-mCOL7 IgG and murine complement C3 was found in both experimental group ( Figure 1F-I) . In the local model, however, mice of both strains began to develop skin lesions at the site of injection 24 hours after treatment. After 48 hours, about 71 ± 8.5% of the skin within the area of the antibody injection was affected in CD11b−/− mice which were comparable to levels seen in wild-type mice ( Fig. S1 in supporting information).
We next determined serum levels of antibodies against rabbit anti-mCOL7 IgG and T-cell-associated cytokines. As shown in Figure 2A , both CD11b−/− mice and wild-type mice generated IgGs against rabbit anti-mCOL7 IgG to comparable extends. Interestingly, sera of CD11b−/− mice contained significantly higher levels of both,
IFN-γ and IL-4 as compared to wild-type controls ( Figure 2B ), while such difference was not observed regarding the levels of IL-10 or IL-17A.
| DISCUSSION
Unexpectedly, CD11b deficiency resulted in an enhanced disease severity at the late phase in chronic antibody transfer-induced EBA.
To our knowledge, our study demonstrates for the first time an antiinflammatory role of CD11b in an experimental autoimmune disease, suggesting that CD11b is involved in the negative regulation of the inflammatory response. Although not seen previously in models of autoimmunity, an anti-inflammatory role of CD11b has been reported in infectious disorders. In 2010, Han et al [11] could show that CD11b deficiency enhances TLR-mediated responses in macrophages, rendering mice more susceptible to endotoxin shock and E. coli-caused sepsis.
According to our results, CD11b deficiency affects disease severity specifically at later stages in our systemic model while no 
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